ArticleCancer research communications2026
Integrated Single-Cell Whole-Genome Sequencing and Spatial Transcriptomics Reveal Intratumoral Heterogeneity in Ovarian Cancer.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal AI in high-grade serous ovarian cancer: integrated prediction and clinical decision-making.Frontiers in oncology · 2026Review
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
The mortality rate of ovarian cancer remains disproportionately high compared with its incidence. This is partly due to a high level of intratumoral heterogeneity, driven by genomic instability, that promotes disease recurrence and treatment failure. In this study, we describe degrees of heterogeneity revealed by single-cell whole-genome sequencing and spatial transcriptomics (ST) of five late-stage, treatment-naïve primary epithelial ovarian carcinomas, including high-grade serous and clear-cell subtypes. All samples exhibited widespread copy-number (CN) aberrations, with the greatest intraspecimen diversification in regions of CN gain. Diversification was also associated with whole-genome doubling in all samples. In two samples, we identify persistent, clonal pseudodiploid cells evolutionarily consistent with a premalignant phenotype. In multiclonal samples, we interpret clonal evolution in the context of single-cell CN, loss of heterozygosity analysis, and somatic mutations and correlate these with tissue histology and gene expression programs. In one high-grade serous carcinoma, we identify functionally consequential CN alterations that contribute to molecular diversity, cell proliferation, and inflammation in a minor clone that persisted without major expansion alongside a more complex major clone. In another clear-cell carcinoma, we describe a complex evolutionary history, including a spontaneous functional reversion of a CTNNB1 driver mutation in a secondary clone, which correlated with a switch in oncogenic expression programs. These examples highlight various consequences of genomic instability on clonal heterogeneity and plasticity in ovarian cancer. SIGNIFICANCE: We utilize single-cell DNA sequencing and ST to illustrate the wide extent of intratumoral heterogeneity within late-stage ovarian tumors. We describe several consequences of chromosomal instability, including divergent biology in multiclonal tumors, persistence of a premalignant cell population, and functional reversion of an oncogenic driver mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.